ROS1
Rare fusion driver in NSCLC. Targeted by crizotinib, entrectinib, repotrectinib.
No Clinical Trials found for this biomarker.
Rare fusion driver in NSCLC. Targeted by crizotinib, entrectinib, repotrectinib.
No Clinical Trials found for this biomarker.